-$0.10 EPS Expected for Genocea Biosciences Inc (GNCA) This Quarter
Analysts predict that Genocea Biosciences Inc (NASDAQ:GNCA) will announce earnings of ($0.10) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Genocea Biosciences’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.13). Genocea Biosciences posted earnings per share of ($0.59) in the same quarter last year, which indicates a positive year-over-year growth rate of 83.1%. The business is scheduled to announce its next earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.49) per share for the current year, with EPS estimates ranging from ($0.49) to ($0.48). For the next financial year, analysts expect that the business will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.82) to ($0.35). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08.
GNCA stock traded down $0.02 during trading on Tuesday, reaching $0.62. The stock had a trading volume of 254,300 shares, compared to its average volume of 820,540. Genocea Biosciences has a 1-year low of $0.56 and a 1-year high of $5.70. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.84 and a quick ratio of 6.84. The firm has a market capitalization of $55.44 million, a P/E ratio of -0.31 and a beta of 1.03.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its position in shares of Genocea Biosciences by 166.6% in the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 78,469 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Genocea Biosciences in the 4th quarter worth about $145,000. LMR Partners LLP bought a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $175,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Genocea Biosciences in the 1st quarter worth about $177,000. Finally, Birchview Capital LP increased its position in shares of Genocea Biosciences by 384.6% in the 1st quarter. Birchview Capital LP now owns 189,000 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 150,000 shares during the last quarter. 60.23% of the stock is owned by institutional investors.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Story: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.